Guideline Recommendations for Antibiotic Use in Nephrotic Syndrome

Prophylactic Antibiotic Recommendations

• The KDIGO 2021 guideline recommends that patients with nephrotic syndrome who receive high‑dose immunosuppressive therapy (e.g., prednisone, rituximab, cyclophosphamide) should be considered for prophylactic trimethoprim‑sulfamethoxazole to reduce infection risk. 1

Vaccination Recommendations

• According to KDIGO 2021, all patients with nephrotic syndrome should receive pneumococcal and seasonal influenza vaccinations as part of routine preventive care. 1

Infection Risk Profile

• Kidney International data (2007) indicate that individuals with nephrotic syndrome have a markedly increased risk of bacterial infections, particularly cellulitis and spontaneous bacterial peritonitis. 3

Investigational Immunomodulatory Use of Azithromycin

• The KDIGO 2025 update notes that the use of azithromycin for its immunomodulatory properties in nephrotic syndrome remains investigational and is not incorporated into current major guideline recommendations; clinicians should document the indication when prescribing. 4

Renal Safety of Macrolide Antibiotics

• The International Journal of Oral Science (2017) clarifies that azithromycin’s renal safety profile differs from that of nephrotoxic antibiotics such as aminoglycosides; macrolides should not be assumed to be inherently nephrotoxic. 5

Drug Interaction Considerations

• KDIGO 2021 highlights a clinically important interaction between azithromycin and warfarin, which may be relevant for nephrotic syndrome patients receiving anticoagulation for thromboembolic risk. 6
• Additional KDIGO 2021 evidence stresses the need to monitor for potential azithromycin‑warfarin interactions, as they can affect anticoagulant control in this population. 7